Notice of Product Exclusion Extensions: China’s Acts, Policies, and Practices Related to Technology Transfer, Intellectual Property, and Innovation
In prior notices, the U.S. Trade Representative modified the action in the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation by excluding from additional duties certain medical-care products needed to address the COVID-19 pandemic. These exclusions are scheduled to expire on September 30, 2021. On August 27, 2021, USTR requested comments on whether to extend these exclusions for up to six months. This notice announces the U.S. Trade Representative’s determination to adopt an interim extension of these exclusions for 45 days in order to provide time to review the public comments.
The extensions announced in this notice will extend the product exclusions through November 14, 2021.
For further information, please contact:
For general questions about this notice, contact Associate General Counsel Philip Butler or Assistant General Counsel David Salkeld at (202) 395-5725. For specific questions on customs classification or implementation of the product exclusions, contact firstname.lastname@example.org.
For full notice, click here.
For more information on COVID Exclusions, click here.
Source: Office of the United States Trade Representative (USTR)